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Antibiotic resistance as a global public health problem
The advent of antibiotics for treating bacterial infections 
is  considered  one  of  the  major  advances  in  modern 
medicine. However, compared with other drugs, the life­
time of antibiotics for clinical use has been substantially 
limited  by  the  phenomenon  of  antibiotic  resistance. 
Failures of antimicrobial chemotherapy due to resistance 
were observed soon after the introduction of penicillin in 
clinical practice and, thereafter, the emergence of resis­
tance has always followed the release of new antibiotics, 
posing a major clinical challenge and at the same time 
acting as a major driver for drug discovery and develop­
ment in the field of antimicrobial agents.
Antibiotic  resistance  is  now  recognized  as  a  major 
public  health  problem  because  of  its  magnitude  and 
global  scale.  In  fact,  resistance  does  not  affect  only 
industrialized countries (where this is expected given the 
unlimited access to the antibiotic market) but also low­
income settings, where resistance rates have been found 
to  be  even  higher  because  of  less  well  regulated  anti­
microbial  policies  and  worse  hygiene  conditions  and 
infection­control practices [1]. It is also well documented 
that  resistance  has  a  significant  impact  in  terms  of 
morbidity, mortality and healthcare­associated costs [2]. 
For  instance,  infections  caused  by  methicillin­resistant 
Staphylococcus  aureus  (MRSA,  one  of  the  most  wide­
spread and challenging resistant superbugs) were shown to 
be associated with an increased risk of mortality (almost 
twofold for bacteremias; more than threefold for surgical­
site infections) in comparison with infections of the same 
type caused by methicillin­susceptible S. aureus (MSSA). 
There is also a positive correlation with the length of stay 
in hospital and the healthcare­associated costs of handling 
MRSA infections compared with MSSA infections [2].
Although antibiotic resistance continues to evolve at a 
steady  pace  and  the  spreading  of  resistant  strains  has 
been  facilitated  by  increasing  international  travel  and 
migration,  most  pharmaceutical  companies  have  also 
recently  chosen  to  restrict  programs  aimed  at  the 
discovery and development of new antibiotics. This has 
plunged the phenomenon of antibiotic resistance into a 
major  crisis,  with  the  increasing  emergence  of  strains 
that  are  resistant  to  most  or  all  antibiotics  currently 
available for clinical use [3], which threatens to turn the 
clock back to the pre­antibiotic era.
Here,  we  briefly  review  and  discuss  how  the  recent 
advance  ment of bacterial genomic sciences can contri­
bute to further current knowledge on resistance and to 
find new solutions to address this important problem.
The genetics of antibiotic resistance
Acquired antibiotic resistance can be due to a plethora of 
mechanisms (Table 1). These include, first, drug inactiva­
tion, for example by β­lactamases and aminoglycoside­
modifying enzymes, which confer resistance to β­lactams 
and  aminoglycosides,  respectively;  second,  drug  target 
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or RNA polymerase modifications, conferring resistance 
to  quinolones  and  rifampicin,  respectively;  third,  drug 
target  protection,  for  example  ribosomal  methylation 
confer  ring resistance to aminoglycosides or macrolides, 
or topoisomerase protection by Qnr proteins conferring 
resistance to quinolones; fourth, drug target bypass, for 
example  peptidoglycan  synthesis  by  a  novel  penicillin­
binding­protein, PBP2a, conferring resistance to β­lactams; 
fifth,  impermeability,  for  example  by  loss  of  outer 
membrane  porin  channels,  conferring  resistance  to 
carba  penems; and finally drug efflux, for example by Tet 
major facilitator superfamily (MFS)­type pumps, confer­
ring resistance to tetracyclines, or by tripartite resistance­
nodulation­cell division superfamily (RND)­type pumps, 
conferring a multidrug resistance phenotype. This diver­
sity of resistance mechanisms reflects the broad reper­
toire of available agents, the multiplicity of their mecha­
nisms of action, the biological diversity of bacteria, and 
the  plasticity  of  their  genomes.  From  a  genetic  stand­
point, resistance mechanisms can arise either by muta­
tion or by the acquisition and expression of heterologous 
genes  encoding  the  resistance  determinant  through 
horizontal gene transfer mechanisms such as conjugation, 
transformation or phage transduction.
Once  acquired,  the  resistance  determinants  confer  a 
selective  advantage  to  the  host  when  it  is  exposed  to 
antibiotics,  which  can  result  in  an  expansion  of  the 
resistant clone relative to susceptible ones; this expansion 
can  assume  epidemic  or  even  pandemic  dimensions. 
Typical  examples  of  resistant  clones  of  Gram­positive 
patho  gens  that  underwent  an  international  dissemina­
tion, with remarkable clinical and epidemiological impact, 
include the MRSA strains belonging to clonal complexes 
(CCs) 5 and 8 [4], the glycopeptide­resistant Enterococcus 
faecium strains of CC17 [5] and the several penicillin­
nonsusceptible pneumococcal clones spread  ing worldwide 
[6]. Similar examples of resistant clones of Gram­negative 
pathogens  with  high  spreading  potential  include  the 
Escherichia  coli  clone  O25:H4­ST­131,  which  produces 
the  CTX­M­15  extended­spectrum  β­lacta  mase  (ESBL) 
[7], the Klebsiella pneumoniae clone (KPC) ST­258, which 
produces acquired KPC­type carbapene  mases [8], and the 
Acinetobacter baumannii derivatives of major  European 
clone II, which produces oxacillin (OXA)­type carbapene­
mases [9].
Table 1. Examples of clinically relevant resistance mechanisms in major bacterial pathogens
Resistance mechanism  Molecular basis  Antibiotics affected  Relevant clinical pathogens 
Drug inactivation   β-Lactamases  β-Lactams (variable spectrum,   Many Gram-positive and Gram-negative 
    depending on the enzyme type)  pathogens
  Aminoglycoside-modifying   Aminoglycosides (variable  Many Gram-positive and Gram-negative 
  enzymes  spectrum, depending on the   pathogens 
    enzyme type)
Target modification  Mutated DNA topoisomerases  Quinolones and fluoroquinolones  Many Gram-positive and Gram-negative  
      pathogens
  Mutated RNA polymerase  Rifampin  Staphylococcus aureus, 
      Mycobacterium tuberculosis
  Altered peptidoglycan   Glycopeptides  Enterococci 
  (presence of d-Ala-d-Lac 
  depsipeptide) 
Target protection  23S ribosomal RNA methylation   Macrolides  Streptococci, Staphylococci, anaerobes 
  by Erm methylases 
  16S ribosomal RNA methylation   Aminoglycosides  Enterobacteriaceae 
  by Arm/Rmt-like methylases
  Ribosomal protection by Tet proteins  Tetracyclines  Many Gram-positive pathogens
  Topoisomerase protection by   Quinolones and fluoroquinolones  Enterobacteriaceae 
  Qnr proteins
Bypass of target function  Production of PBP2a, which takes over   Most β-lactams  Methicillin-resistant Staphylococcus aureus
  the functions of other PBPs     (MRSA)
Impermeability  Loss of OprD porin  Carbapenems  Pseudomonas aeruginosa
Drug efflux  Tet MFS-type pumps  Tetracyclines  Enterobacteriaceae, Staphylococci
  Upregulation of MexAB RND-type   Fluoroquinolones and most  Pseudomonas aeruginosa
  pump  anti-pseudomonal β-lactams 
  Upregulation of MexXY RND type pump  Fluoroquinolones, aminoglycosides,   Pseudomonas aeruginosa
    cefepime and meropenem
PBP: penicillin-binding-protein.
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transposons  and  lysogenic  bacteriophages,  can  also  be 
very  successful  in  transferring  across  different  strains, 
leading to a multi­clonal emergence of resistant strains. A 
typical  example  is  represented  by  several  conjugative 
plasmids encoding CTX­M­type ESBLs that were respon­
sible for rapid and efficient dissemination of these resis­
tance determinants, conferring resistance to the expanded­
spectrum  cephalosporins,  among  E.  coli  [10].  Other 
examples  of  mobile  genetic  elements  that  contributed 
significantly  to  horizontal  dissemination  of  resistance 
genes are the large conjugative transposons and phage­like 
elements  carrying  macrolide  resistance  determinants  of 
the erm and mef type, responsible for the dissemination of 
these resistance determinants among different clones of 
pneumococci and group A strepto  cocci [11].
The role of genomics in surveillance and control of 
resistance
Tracing the epidemiology of resistant strains and resis­
tance genes is of paramount importance for surveillance 
and control of antibiotic resistance, which can no longer 
rely  on  the  simple  phenotypic  characterization  of 
bacterial  isolates.  Molecular  epidemiology  is  the  disci­
pline  that  studies  the  epidemiology  of  resistant  strains 
and  resistance  genes  by  characterizing  them  at  the 
molecular level, and it has provided major breakthroughs 
in the understanding of this phenomenon, with practical 
implications for resistance control strategies. The infor­
ma  tion  provided  by  molecular  analysis  has  a  variable 
degree of resolution depending on the analytical tools, 
with genetic ones being the most versatile and of highest 
resolution. From this perspective, full genomic analysis of 
major  resistant  clones  can  be  very  informative  for 
understanding their lifestyle and evolution and would be 
the golden standard for their comparison, as it was clearly 
shown with MRSA [12].
Genomic knowledge can also be instrumental to the 
development  of  sets  of  molecular  probes  for  easy  and 
specific identification of resistant clones of high spread­
ing  propensity  and  clinical  impact,  such  as  those 
described  above,  which  is  crucial  in  infection  control 
practices. These probes can be used by reference labora­
tories or even by the largest diagnostic laboratories, in 
multiplexed amplification or DNA microarray technolo­
gies, for identification of such ‘high risk’ resistant clones 
involved in hospital or community outbreaks.
The importance of identifying high risk resistant clones 
and  understanding  their  evolution  explains  the  con­
siderable  effort  that  has  recently  been  undertaken  to 
sequence  the  genomes  of  multiresistant  strains  of 
bacterial pathogens [13], such as MRSA (eight projects), 
Acinetobacter baumannii (five projects), Mycobacterium 
tuberculosis (three projects) and Pseudomonas aeruginosa 
(two projects), and also to sequence plasmids involved in 
the dissemination of important resistance determinants, 
such as ESBLs, AmpC­type β­lactamases or (quinolone 
resistance) Qnr proteins [14].
Genomics can inform our understanding of 
resistance mechanisms
Understanding resistance mechanisms to novel drugs is 
crucial in the process of discovery and development of 
antimicrobial  drugs.  Knowledge  on  newly  emerging 
resistance mechanisms to antibiotics already available for 
clinical  use  is  also  of  paramount  importance  for  the 
prediction of resistance evolution, antibiotic policies and 
resistance surveillance and control strategies. Genome­
scale  investigations  may  provide  relevant  insights  into 
unknown mechanisms of antibiotic resistance.
For instance, a comparative genomic analysis between 
S. aureus strains showing heterogeneous or homogeneous 
intermediate resistance to vancomycin (hVISA or VISA 
strains)  and  the  susceptible  parent  strain  has  recently 
revealed the role of mutations of the genes encoding the 
vraSR  and  graSR  two­component  regulatory  system  in 
conferring this resistance phenotype, which is associated 
with  clinical  failures  of  glycopeptides  [15].  A  similar 
comparative genomic approach, carried out using array­
based  methodology,  provided  insights  into  mutational 
mechanisms that, in S. aureus, could be responsible for 
the emergence of reduced susceptibility to daptomycin, a 
new anti­Gram­positive antibiotic recently released for 
the treatment of staphylococcal infections [16]. Another 
genome­scale investigation that advanced our knowledge 
of resistance mechanisms was that by Breidenstein et al. 
[17], who, using a comprehensive P. aeruginosa mutant 
library,  identified  a  number  of  new  genes  that,  when 
inactivated, are associated with decreased susceptibility 
to fluoroquinolones in this species. These genes include 
PA2047  and  PA3574,  which  encode  transcriptional 
regulators, the nuo genes, which encode NADH dehydro­
genase  I  subunits,  and  several  other  genes  encoding 
hypo  thetical proteins.
Transcriptomics at a genome­wide scale has also been 
used successfully to investigate resistance mechanisms. 
For  example,  transcription  profiling  following  cipro­
floxacin exposure has revealed an important role of the 
mfd gene, which encodes a transcription­repair coupling 
factor  involved  in  strand­specific  DNA  repair,  in  the 
development of fluoroquinolone resistance in Campylo­
bacter  jejuni  [18].  Transcriptome  analysis  of  S.  aureus 
treated  with  sublethal  concentrations  of  cationic  anti­
microbial peptides has revealed a role for several genes, 
including  the  vraSR  cell  wall  regulon,  in  the  bacterial 
response to these agents, as well as a role of the VraDE 
putative  ATP­binding  cassette  (ABC)  transporter  in 
confer  ring resistance to bacitracin [19].
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discovery
Knowledge on bacterial genomes has progressed at a fast 
pace during recent years, with almost 1,500 completed 
bacterial genomes and more than 600 additional genome 
projects in progress at the beginning of 2010 [13]. Indeed, 
since its very beginning, the advent of bacterial genomics 
was not only regarded as a fascinating scientific tool, but 
also raised great hopes for renewing the golden era of 
antimicrobial  discovery  at  a  time  when  this  is  sorely 
needed  because  of  the  growing  impact  of  bacterial 
resistance. The rationale behind this expectation was that 
comparative  genomic  analysis  could  reveal  valuable 
information on bacterial genes that presumably encode 
proteins  that  are  essential  to  survival  or  fitness  of 
bacterial  pathogens  and  do  not  have  close  eukaryotic 
counterparts;  these  proteins  could  then  be  potential 
targets for new antimicrobial agents.
This  approach  has  been  extensively  pursued  and  has 
returned  some  potential  targets  for  new  antimicrobial 
agents that fulfilled the above criteria, including enzymes 
involved in biosynthetic pathways (for example coenzyme 
A, chorismate, lipid A and fatty acids), protein synthesis 
(such as aminoacyl tRNA synthetases and peptide defor­
mylase),  protein  secretion  (such  as  signal  peptidase  1) 
and DNA replication (such as FtsZ/FtsA) [20,21]. Some 
two­component  signal  transduction  systems  have  also 
been considered [20].
However, it was soon evident that, although identifi­
cation of potential targets is important, a comprehensive 
understanding of bacterial biochemistry, physiology and 
pathogenicity are essential for exploiting this information 
for antimicrobial drug discovery. After the identification 
of the potential targets, there are several bottlenecks to 
be overcome in the process of developing new drugs; in 
particular, the need to set up high­throughput screening 
of  banks  of  small  molecules  to  obtain  potential  hits, 
which  has  prompted  great  efforts  in  the  fields  of 
functional and structural genomics [22]. Moreover, many 
screenings have turned out to be unproductive, or it was 
discovered that effective drugs could not be developed 
from the potential inhibitors [20].
This  accounts  for  the  overall  dearth  of  new  drugs 
discovered using genomic approaches that have made it 
into advanced clinical phases of the antibiotic pipeline 
after almost 15 years of efforts in this area. However, the 
natural  products  platensimycin  and  platenmycin, 
produced  by  Streptomyces  platensis,  have  been  dis­
covered to be inhibitors of FabF and/or FabH (enzymes 
involved in bacterial type II fatty­acid biosynthesis) [23] 
and  are  now  awaiting  further  preclinical  studies,  and 
some peptide deformylase inhibitors have already entered 
clinical trials [20,21]. Therefore, the potential of microbial 
genomics  for  discovery  of  new  drugs  should  not  be 
underestimated.  Indeed,  a  novel  screening  technique, 
combining chemical genomics with a yeast­based assay, 
has  enabled  the  discovery  of  both  a  P.  aeruginosa 
virulence­associated target (ExoS) and its inhibitor [24].
Finally,  cloning  and  sequencing  metagenomes  from 
various ecological niches in which antibiotic­producing 
bacteria  are  expected  to  be  present  could  reveal  new 
antimicrobial synthetic gene clusters from unknown or 
uncultured  bacteria.  This  strategy  has  already  yielded 
some results such as the gene clusters for synthesis of 
turbomycins  A  and  B,  new  glycopeptides  and  other 
compounds  with  antimicrobial  activity  cloned  from 
environmental DNA (eDNA) libraries [25].
Concluding remarks
Antibiotic  resistance  is  one  of  the  greatest  clinical 
challenges in the treatment of infectious diseases, given 
that it is a complex phenomenon whose emergence and 
evolution  is  still  only  partially  understood.  Bacterial 
genomics  provides  an  invaluable  contribution  to 
furthering  current  knowledge  on  antibiotic  resistance 
mecha  nisms and evolution, and on molecular epidemio­
logy  of  resistance,  which  is  instrumental  to  infection 
control practices. Moreover, information from functional 
and  structural  genomics  has  a  key  role  in  the  identi­
fication  of  novel  antimicrobial  targets.  The  number  of 
new agents discovered following this approach that are 
found in the advanced stages of the antibiotic pipeline is 
still very limited; however, the exploitation of bacterial 
genomics has been a major breakthrough for discovery 
and  development  of  new  antibiotics  active  against 
multiresistant pathogens.
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